Trials in Long Beach, California
Here are the top 10 medical studies for lung cancer in Long Beach, California
Popular Filters
Phase 3 Trials
Small Molecule Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Long Beach, California
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Chemotherapy
Immunotherapy + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Whittier, California
This trial is testing two new drugs, zimberelimab and domvanalimab, combined with chemotherapy for patients with advanced lung cancer that has spread and lacks specific genetic targets. These drugs help the immune system better recognize and attack cancer cells. The goal is to see if this combination improves survival compared to another drug, pembrolizumab, with chemotherapy.
Monoclonal Antibodies
Serplulimab + Chemotherapy for Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Long Beach, California
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Taxane
Ceralasertib + Durvalumab for Lung Cancer
Recruiting3 awardsPhase 3
Los Alamitos, California
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Trials With No Placebo
EGFR-TKI agent
JIN-A02 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Orange, California
This trialwill evaluate the safety and effectiveness of a 4th gen EGFR-TKI agent for advanced NSCLC with EGFR mutations. Subjects will be tested for EGFR mutants and receive doses based on safety & anti-tumor activity.
Small Molecule Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Long Beach, California
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Small Molecule Inhibitor
RMC-6236 for Cancer
Recruiting1 awardPhase 1
Orange, California
This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
Tyrosine Kinase Inhibitor
Furmonertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Whittier, California
This trial is testing furmonertinib, a medication for advanced lung cancer patients with specific genetic mutations. It aims to see if the drug can block signals that make cancer cells grow, potentially slowing down or stopping the cancer. Furmonertinib was recently approved in China for treating patients with advanced lung cancer with confirmed genetic mutations.
Chemotherapy
Tarlatamab Combo for Small Cell Lung Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing a new drug called tarlatamab combined with treatments that help the immune system fight cancer, and sometimes with chemotherapy. It targets cancer patients who need new treatment options. Tarlatamab attacks cancer cells directly, while other treatments boost the immune response or kill cancer cells.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.